JP2022539840A5 - - Google Patents
Info
- Publication number
- JP2022539840A5 JP2022539840A5 JP2022500764A JP2022500764A JP2022539840A5 JP 2022539840 A5 JP2022539840 A5 JP 2022539840A5 JP 2022500764 A JP2022500764 A JP 2022500764A JP 2022500764 A JP2022500764 A JP 2022500764A JP 2022539840 A5 JP2022539840 A5 JP 2022539840A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201930643 | 2019-07-10 | ||
| ESP201930643 | 2019-07-10 | ||
| PCT/EP2020/069459 WO2021005183A1 (en) | 2019-07-10 | 2020-07-09 | Inhibitor of map kinase interacting serine/threonine kinase 1 (mnk1) and map kinase interacting serine/threonine kinase 2 (mnk2), cancer therapy and therapeutic combinations |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022539840A JP2022539840A (ja) | 2022-09-13 |
| JPWO2021005183A5 JPWO2021005183A5 (https=) | 2023-07-18 |
| JP2022539840A5 true JP2022539840A5 (https=) | 2023-07-18 |
| JP7536243B2 JP7536243B2 (ja) | 2024-08-20 |
Family
ID=71607975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022500764A Active JP7536243B2 (ja) | 2019-07-10 | 2020-07-09 | Ｍａｐキナーゼ相互作用セリン／スレオニン－プロテインキナーゼ１（ｍｎｋ１）及びｍａｐキナーゼ相互作用セリン／スレオニン－プロテインキナーゼ２（ｍｎｋ２）の阻害剤、癌治療及び治療的組合せ |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220257571A1 (https=) |
| EP (1) | EP3996710B1 (https=) |
| JP (1) | JP7536243B2 (https=) |
| ES (1) | ES3014017T3 (https=) |
| WO (1) | WO2021005183A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11958832B1 (en) | 2023-10-12 | 2024-04-16 | King Faisal University | 2-alkoxy[4,3:6,3-terpyridine]-3-carbonitriles as antimicrobial compounds |
| US11926611B1 (en) | 2023-11-24 | 2024-03-12 | King Faisal University | 2-(2-ethoxyethoxy)-6-phenyl-4,4′-bipyridine-3-carbonitrile as an antimicrobial compound |
| US12071407B1 (en) | 2023-12-05 | 2024-08-27 | King Faisal University | 6-(4-hydroxyphenyl)-2-(2-ethoxyethoxy)-4-(4-methoxyphenyl)nicotinonitrile as an antimicrobial compound |
| US11970451B1 (en) | 2023-12-07 | 2024-04-30 | King Faisal University | 6-(3-hydroxyphenyl)-2-methoxy-4-(3-methylphenyl)nicotinonitrile as an antimicrobial compound |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2160780A1 (de) | 1971-12-08 | 1973-06-14 | Basf Ag | Pyridino-pyrazole |
| US20100113415A1 (en) * | 2008-05-29 | 2010-05-06 | Rajapakse Hemaka A | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
| EP2464647B1 (en) | 2009-08-11 | 2016-09-21 | Bristol-Myers Squibb Company | Azaindazoles as btk kinase modulators and use thereof |
| AU2014289415A1 (en) | 2013-07-08 | 2016-01-21 | Bayer Pharma Aktiengesellschaft | Substituted pyrazolo-pyridinamines |
| US10702526B2 (en) * | 2015-04-20 | 2020-07-07 | Effector Therapeutics Inc. | Inhibitors of immune checkpoint modulators and related methods |
-
2020
- 2020-07-09 ES ES20739952T patent/ES3014017T3/es active Active
- 2020-07-09 JP JP2022500764A patent/JP7536243B2/ja active Active
- 2020-07-09 US US17/625,075 patent/US20220257571A1/en not_active Abandoned
- 2020-07-09 WO PCT/EP2020/069459 patent/WO2021005183A1/en not_active Ceased
- 2020-07-09 EP EP20739952.8A patent/EP3996710B1/en active Active